What alternative biologics or targeted synthetic DMARDs can be used for a patient with RF positive RA, intolerant to MTX, with hair loss on Rinvoq (Upadacitinib), and no coverage for Xeljanz (Tofacitinib), who has previously used Actemra (Tocilizumab)?

Alternative Treatment Options for RF-Positive RA with Multiple Drug Intolerances

Direct Recommendation

Switch to a TNF inhibitor (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) combined with leflunomide or sulfasalazine as the anchor DMARD, since this patient cannot tolerate MTX and has failed two JAK inhibitors (Xeljanz and Rinvoq) and previously used Actemra. 1, 2

---

Treatment Algorithm for This Complex Case

Step 1: Select Alternative Anchor DMARD (MTX Replacement)

Since MTX is not tolerated, leflunomide is the preferred first alternative with efficacy similar to MTX 2. Sulfasalazine is equally recommended as a first-line MTX alternative 1, 2.

• Leflunomide has the strongest evidence base as an MTX substitute and should be initiated at standard dosing 2
• Sulfasalazine is an acceptable alternative if leflunomide is contraindicated 1, 2
• Injectable gold is a third option but less practical in modern practice 1, 2

Step 2: Add Biologic DMARD

TNF inhibitors combined with the alternative DMARD (leflunomide or sulfasalazine) are the recommended next step 1, 2. The patient has already cycled through:

• Xeljanz (tofacitinib) - no coverage
• Rinvoq (upadacitinib) - caused hair loss
• Actemra (tocilizumab) - previously used

Available TNF inhibitor options include: 1, 2

• Adalimumab (subcutaneous)
• Certolizumab pegol (subcutaneous)
• Etanercept (subcutaneous)
• Golimumab (subcutaneous or IV)
• Infliximab (IV)

Step 3: Alternative Non-TNF Biologics

If TNF inhibitors fail or are contraindicated, the following non-TNF biologics can be used: 1, 3

• Abatacept (IV or subcutaneous) - can be used after TNF failure or as first biologic 1
• Rituximab (IV) - particularly effective in RF-positive patients like this one 1, 3
• Return to Actemra (tocilizumab) if previously effective - the patient has used this before, and if it worked well, rechallenging is reasonable 1, 3

---

Critical Decision Points

Why Not Continue JAK Inhibitors?

The patient has failed two JAK inhibitors (Xeljanz due to coverage, Rinvoq due to hair loss). Hair loss with Rinvoq represents a class effect concern that may recur with other JAK inhibitors 4. Moving to a different mechanism of action (TNF or non-TNF biologics) is the appropriate escalation 1.

Why TNF Inhibitors Before Other Biologics?

EULAR guidelines recommend TNF inhibitors as first-line biologics when MTX/DMARD therapy fails 1. This patient is essentially biologic-naive for TNF inhibitors, making them the logical next choice 1, 2.

Combination vs. Monotherapy

Biologics should NOT be used as monotherapy when a conventional DMARD can be tolerated 1, 2, 3. The combination of biologic + conventional DMARD (leflunomide or sulfasalazine) provides superior efficacy compared to monotherapy 1, 5.

---

Monitoring and Treatment Adjustment

Disease activity must be assessed every 1-3 months during active disease 1, 2:

• If no improvement by 3 months → adjust therapy 1, 2
• If treatment target (remission or low disease activity) not reached by 6 months → change therapy 1, 2

---

Glucocorticoid Bridge Therapy

Add low-dose glucocorticoids (≤10 mg/day prednisone equivalent) when starting the new regimen 2. Taper as rapidly as clinically feasible, ideally within 3-6 months 1, 2.

---

Common Pitfalls to Avoid

1. Do not delay DMARD initiation - start leflunomide or sulfasalazine immediately 2
2. Do not use biologics as monotherapy when conventional DMARDs can be combined 1, 2, 3
3. Screen for tuberculosis and hepatitis B before starting any biologic 3, 6
4. Ensure pneumococcal, influenza, and hepatitis B vaccinations are up to date 6

---

Special Consideration: RF-Positive Status

This patient's RF-positive status is prognostically significant 1. RF-positive patients may have particularly good responses to rituximab if TNF inhibitors fail 3. This should be kept in mind as a strong option if the initial TNF inhibitor strategy is unsuccessful.

---

Insurance Coverage Strategy

Given the coverage denial for Xeljanz, work with the patient's insurance to obtain prior authorization for a TNF inhibitor + leflunomide combination 2. Document:

• MTX intolerance
• Rinvoq failure due to adverse event (hair loss)
• Previous use of Actemra
• RF-positive disease with poor prognostic factors 1

If TNF inhibitors are also denied, rituximab or abatacept combined with leflunomide are evidence-based alternatives 1, 3.